NCT02391545 2023-09-28A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)SecuraBioPhase 1/2 Terminated55 enrolled 13 charts
NCT02292225 2023-02-27Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)SecuraBioPhase 1 Terminated3 enrolled
NCT04209621 2022-03-09Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNational Institutes of Health Clinical Center (CC)Phase 2 Terminated3 enrolled 12 charts